Last reviewed 2026-04-22 · How we verify

nadolol + ISMN

E-DA Hospital · FDA-approved active Small molecule

nadolol + ISMN is a Beta-blocker + Nitrate combination Small molecule drug developed by E-DA Hospital. It is currently FDA-approved for Angina pectoris, Hypertension.

Nadolol reduces heart rate and blood pressure via beta-blockade, while ISMN (isosorbide mononitrate) dilates blood vessels to improve coronary blood flow and reduce cardiac workload.

Nadolol reduces heart rate and blood pressure via beta-blockade, while ISMN (isosorbide mononitrate) dilates blood vessels to improve coronary blood flow and reduce cardiac workload. Used for Angina pectoris, Hypertension.

At a glance

Generic name	nadolol + ISMN
Sponsor	E-DA Hospital
Drug class	Beta-blocker + Nitrate combination
Target	Beta-adrenergic receptors (nadolol); soluble guanylate cyclase (ISMN)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

Nadolol is a non-selective beta-adrenergic antagonist that decreases heart rate, contractility, and blood pressure, reducing myocardial oxygen demand. ISMN is a nitrate vasodilator that relaxes vascular smooth muscle, improving coronary perfusion and reducing preload on the heart. Together, this combination provides complementary cardioprotective effects for angina management.

Approved indications

Angina pectoris
Hypertension

Common side effects

Fatigue
Dizziness
Headache
Bradycardia
Hypotension
Nitrate tolerance

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

nadolol + ISMN CI brief — competitive landscape report
nadolol + ISMN updates RSS · CI watch RSS
E-DA Hospital portfolio CI

Frequently asked questions about nadolol + ISMN

What is nadolol + ISMN?

nadolol + ISMN is a Beta-blocker + Nitrate combination drug developed by E-DA Hospital, indicated for Angina pectoris, Hypertension.

How does nadolol + ISMN work?

Nadolol reduces heart rate and blood pressure via beta-blockade, while ISMN (isosorbide mononitrate) dilates blood vessels to improve coronary blood flow and reduce cardiac workload.

What is nadolol + ISMN used for?

nadolol + ISMN is indicated for Angina pectoris, Hypertension.

Who makes nadolol + ISMN?

nadolol + ISMN is developed and marketed by E-DA Hospital (see full E-DA Hospital pipeline at /company/e-da-hospital).

What drug class is nadolol + ISMN in?

nadolol + ISMN belongs to the Beta-blocker + Nitrate combination class. See all Beta-blocker + Nitrate combination drugs at /class/beta-blocker-nitrate-combination.

What development phase is nadolol + ISMN in?

nadolol + ISMN is FDA-approved (marketed).

What are the side effects of nadolol + ISMN?

Common side effects of nadolol + ISMN include Fatigue, Dizziness, Headache, Bradycardia, Hypotension, Nitrate tolerance.

What does nadolol + ISMN target?

nadolol + ISMN targets Beta-adrenergic receptors (nadolol); soluble guanylate cyclase (ISMN) and is a Beta-blocker + Nitrate combination.

Drug class: All Beta-blocker + Nitrate combination drugs
Target: All drugs targeting Beta-adrenergic receptors (nadolol); soluble guanylate cyclase (ISMN)
Manufacturer: E-DA Hospital — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Angina pectoris
Indication: Drugs for Hypertension

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing